Proceedings of the National Academy of Sciences · 2015 · 34 citations · 60 references
Life SciencesEndocrinologyPharmacologyCell SignalingMetabolic PhysiologyMetabolic RegulationAdipose TissueDiabetes MellitusMetabolic SignalingPancreatic EndocrinologyPancreatic HormonesTriglyceride MetabolismAdipose EndocrinologyGlucagon Receptor AgonismGlucagon Receptor AgonistsGlucagon Receptor AntagonismGlucagon Receptor PharmacologyGlucagon Receptor SignalingInsulin MetabolismWhite Adipose Tissue Biology
Type 2 diabetes is characterized by a reduction in insulin function and an increase in glucagon activity that together result in hyperglycemia. Glucagon receptor antagonists have been developed as drugs for diabetes; however, they often increase glucagon plasma levels and induce the proliferation of glucagon-secreting α-cells. We find that the secreted protein Angiopoietin-like 4 (Angptl4) is up-regulated via Pparγ activation in white adipose tissue and plasma following an acute treatment with a glucagon receptor antagonist. Induction of adipose angptl4 and Angptl4 supplementation promote α-cell proliferation specifically. Finally, glucagon receptor antagonist improves glycemia in diet-induced obese angptl4 knockout mice without increasing glucagon levels or α-cell proliferation, underscoring the importance of this protein. Overall, we demonstrate that triglyceride metabolism in adipose tissue regulates α-cells in the endocrine pancreas.
60